Erectile dysfunction drugs haven’t generated the most noise as likely OTC switch candidates with the US Food and Drug Administration moving toward making digital labeling part of its regulatory framework to make more ingredients available nonprescription.
For Petros Pharmaceuticals, Inc., however, the FDA’s “additional conditions of nonprescription use” proposed rule is a symphony of encouragement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?